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Abstract
Background: Suboptimal activation of T lymphocytes by melanoma cells is often due to the defective expression of class I
major histocompatibility antigens (MHC-I) and costimulatory molecules. We have previously shown that geranylgeranyl
transferase inhibition (done with GGTI-298) stimulates anti-melanoma immune response through MHC-I and costimulatory
molecule expression in the B16F10 murine model [1].
Methodology/Principal Findings: In this study, it is shown that vaccination with mIFN-gand GGTI-298 pretreated B16F10
cells induces a protection against untreated tumor growth and pulmonary metastases implantation. Furthermore, using a
human melanoma model (LB1319-MEL), we demonstrated that in vitro treatment with hIFN-c and GGTI-298 led to the up
regulation of MHC-I and a costimulatory molecule CD86 and down regulation of an inhibitory molecule PD-1L. Co-culture
experiments with peripheral blood mononuclear cells (PBMC) revealed that modifications induced by hIFN-c and GGTI-298
on the selected melanoma cells, enables the stimulation of lymphocytes from HLA compatible healthy donors. Indeed, as
compared with untreated melanoma cells, pretreatment with hIFN-c and GGTI-298 together rendered the melanoma cells
more efficient at inducing the: i) activation of CD8 T lymphocytes (CD8+/CD69+); ii) proliferation of tumor-specific CD8 T
cells (MelanA-MART1/TCR+); iii) secretion of hIFN-c; and iv) anti-melanoma specific cytotoxic cells.
Conclusions/Significance: These data indicate that pharmacological treatment of melanoma cell lines with IFN-c and GGTI-
298 stimulates their immunogenicity and could be a novel approach to produce tumor cells suitable for vaccination and for
stimulation of anti-melanoma effector cells.
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Introduction
Anti-tumor immunotherapies can be roughly subdivided into
two types: passive or active. Passive immunotherapies involve the
use of anti-tumor antibodies [2] or adoptive strategies using the re-
infusion of a patient’s lymphocytes after an in vitro stimulation [3].
Active immunotherapies include the injection of tumor-associated
antigen (TAA) peptides [4] [5], antigen-pulsed dendritic cells (DC)
[6], tumor-DC hybrids [7] or irradiated allogeneic tumor cells [8].
To be really efficient these active immunotherapies should induce
not only effector cells able to immediately kill tumor cells but also
memory effector cells able to prolong the protective response. The
efficiency of irradiated autologous tumor cells in active immuno-
therapy is often limited due to their weak immunogenicity, and in
particular, the frequent down-regulation of membrane class I
MHC (MHC-I) antigens and/or TAA expression [9]. One of
several strategies used to increase tumor immunogenicity and
enhance anti-tumor T-cell response is the use of tumor cells
genetically modified to over-express MHC-I and/or costimulatory
molecules [8] [10]. However, these strategies are difficult to adapt
to large-scale human clinical trials.
Instead, pharmacological treatments capable of increasing tumor
immunogenicity have been sought [11] [12]. GGTI-298 is a
pharmacological inhibitor of geranylgeranyl transferase type I
enzyme. This enzyme covalently binds geranylgeranyl pyrophos-
phate, an isoprenoid compound of the mevalonate pathway, to
numerous proteins of the Ras super family including Rho proteins.
This posttranslational binding is required for the activity of a large
scale of proteins [13], and geranylgeranyl transferase type I inhibition
by GGTI-298 is known to inhibit growth [14], cell cycle [15] or
migration in several tumor models [16]. Furthermore, it was recently
shown that a novel GGTI inhibitor (P61A6) significantly suppress in
vivo tumor growth, in a human pancreatic cancer xenograft model in
mice [17]. We previously demonstrated [1] that murine B16F10
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treatment by mIFN-c in association with GGTI-298, characterized
by an up regulation of MHC-I and the GGTI-induced expression of
CD80 and CD86 costimulatory molecules. Moreover, this treatment
enables the T-cell-induced reduction of tumor growth in syngeneic
immunocompetent mice and enhanced levels of B16F10 specific
CD8 T lymphocytes TRP-2/H-2K
b TCR
+ [1].
These results may provide the basis for new therapeutic
strategies that would involve the ex vivo pharmacological treatment
of melanoma cells with IFN-c and GGTI-298 to produce useful
cells for vaccination or adoptive transfer therapies. However, two
essential points remained to be tested. First, in the murine model
whether these pharmacological treatments produce immunogenic
melanoma cells useful for in vivo vaccination. Then, to test in a
suitable model whether these treatments are also efficient with
human melanoma cells. In human models the evaluation of the
increased immunogenicity of the treated melanoma cells have to
be done in vitro. Therefore, it must be tested by co-cultures with
HLA compatible lymphocytes whether these treatments would
sufficiently modify the human melanoma cells to enable the
induction of specific anti-tumor cytotoxic effector cells.
In the present study, we therefore used a human melanoma cell
line (LB1319-MEL) expressing the EAAGIGILTV peptide,
obtained from MelanA/MART-1 proteins, on HLA-A0201
molecules. These cells are particularly suitable for pre-clinical
trials, since: i) HLA-A0201 is the most frequent MHC-I haplotype
expressed in the Caucasian population; ii) MelanA/MART-1
protein is expressed on a large proportion of human melanoma
cells [18]; and iii) the EAAGIGILTV peptide represents a prime
target for immunotherapeutic protocols [19].
Our results show in the B16F10 murine model, that
pharmacologically treated melanoma cells become useful tools
for in vivo vaccination, inducing protection against tumor growth
and pulmonary metastasis implantation. Furthermore, in vitro
treatment of LB1319-MEL cells with hIFN-c and GGTI-298
induces modifications in these cells which enable the stimulation in
vitro of co-cultivated HLA-A0201 compatible peripheral blood
mononuclear cells (PBMC) from healthy donors (HD). This
stimulation induces the enhancement of tumor-specific CD8 T
cells, the production of IFN-c and the enhancement of the
cytotoxic response. These results suggest that our treatments could
be a novel strategy to enhance melanoma immunogenicity and to
produce cells possibly useful for immunotherapies.
Materials and Methods
Tumor Cell Lines and Animals
LB1319-MEL human melanoma cell line was kindly provided
by Professor T. Boon (Ludwig Institute for Cancer Research,
Brussels). Human leukemic Jurkat cells and B16F10 murine
melanoma cell line were purchased from the American Type
Culture Collection. These tumor cell lines were maintained in
culture by serial passages in culture medium composed of RPMI
1640 medium (Gibco-BRL) supplemented with 10% FCS, 1 mM
glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin
sulfate (Invitrogen Life Technologies). Cell lines were periodically
tested to be mycoplasm-free. Six- to 8-wk-old female C57Bl/6
mice were obtained from Elevages Janvier. Mice were maintained
in pathogen-free conditions, and studies were performed in
accordance with local ethical guidelines.
In Vitro Pharmacological Treatment of Tumor Cells
Melanoma cells (1610
5) were cultivated for 4 days in 6-well
plates (Dutsher) in 2 mL of culture medium. Murine or human
IFN-c (mIFN-c or hIFN-c) (50 UI/mL) (Roche) and GGTI-298
(10 mM) (Calbiochem) were added alone or in combination.
Vaccination and Analysis of Murine Tumor Growth
Naı ¨ve C57BL/6 mice were vaccinated by a single sub-cutaneous
(s.c.) injection with 2610
5 irradiated (100 Gy) B16F10 cells. Before
irradiation these melanoma cells were in vitro pretreated during 4
days with mIFN-c (50 IU/mL), GGTI-298 (10 mM) or both
products and then washed twice to completely remove the unfixed
products. One month after this vaccination, mice were challenged
and checked for s.c. tumor growth and for pulmonary metastases
implantation. To study the tumor growth, mice received a tumor
challenge with 1610
5 live untreated B16F10 cells injected sub-
cutaneously. Animals were monitored for tumor growth every 3
days by palpation, and diameters of the tumors were measured
using a Vernier caliper. Tumor-bearing animals were sacrificed
when the tumors displayed severe ulceration or reached a size of
400 mm
2. In the case of tumor-free mice, experiments were
terminated 9 weeks after tumor challenge. All experiments included
6–8 mice/group. To study pulmonary metastases implantation,
vaccinated mice were injected intravenously with 5610
4 live
untreated B16F10 cells and sacrificed 15 days later. Macroscopic
metastases were detected visually and microscopic metastases were
quantified. The lungs were fixed in formalin (24 h), then slidded
vertically and paraffin imbedded. Four mm sections were routinely
stained by hemalun and eosin. The number of metastases was
assessed andreported to the lung surfaces. Theexperimentsonmice
have been done in the appropriate conditions of husbandry,
experimentation and care, because our animal house is controlled
by an ethic comity. And our protocols were validated by the Ethic
comity of the Institut Claudius Regaud under the control of the
Regional Comity of Midi-Pyre ´ne ´es (France). They received the
agreement number : ICR-2009-0019.
Flow Cytometric Analyses
For the flow cytometric analyses, PE-conjugated anti-HLA-
ABC, anti-HLA-A0201, anti-HLA-DPDQDR, anti-TAP1, anti-
TAP2, anti-CD69, anti-CD86, anti-PD-1L and anti-CD107a
monoclonal antibodies were purchased from BD Pharmingen.
FITC-conjugated anti-CD8 and PE-conjugated MART-1-HLA-
A2 and EBV-HLA-A2 tetramers were purchased from Beckman
Coulter. Stained cells were analyzed on a FACS Calibur (BD
Pharmingen). To evaluate membrane antigen expression, the
index of specific fluorescence (ISF) was determined. This was
calculated using the following formula: (Median Fluorescence
Intensity (MFI) with the specific antibody – MFI with the isotype
control/MFI with the isotype control).
Western Blot Analysis
Protein extracts were prepared by the standard procedure and
then separated (40 mg protein/lane) on SDS-PAGE gels. Proteins
were blotted onto PVDF membranes. The filters were incubated
at 4uC overnight with primary antibodies against TAP1, TAP2,
Tapasin, Pa28b, LMP10 (Santa Cruz Biotech) and LMP2 or
LMP7 (Abcam). Actin was used as a loading control. The
membranes (Bio-Rad) were then incubated with horse radish
peroxidase-labeled secondary antibody (Jackson Immuno Re-
search) for 1 h at room temperature and then detected by
chemiluminescence.
In Vitro Stimulation of PBMC from Healthy Donors
Volunteer healthy donors (HD) were leukapheresed after
informed consent. The purification of PBMC was done by
IFN-c+GGTI Melanoma Treatment
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HLA-0201+ donors were selected and then twice stimulated in vitro
for 7 days in 24-well plates (Dutsher) at 37uC in a 5% CO2
humidified atmosphere in culture medium. These stimulations
were performed by incubating 2610
6 PBMC with 2610
4
irradiated (100 Gy) LB1319-MEL melanoma cells pretreated with
hIFN-c (50 IU/mL) and/or GGTI-298 (10 mM). Before co-
culture, the pretreated tumor cells were washed twice to
completely remove the hIFN-c and GGTI-298. During the
second stimulation and after 3 days of co-culture, 50 IU/mL of
human IL-2 (hIL-2r, Proleukin, Chiron) was added.
Analysis of Cytokine Secretion during In Vitro Stimulation
of PBMC
Concentrations of cytokines (IL-2, IFN-c, IL-4 and IL-10) were
assayed in culture supernatant using the Bio-Plex suspension array
system (Bio-Rad). Cytokine levels were measured using Bio-Plex
human cytokine assays according to the manufacturer’s instruc-
tions. Data were analyzed using the Bio-Plex Manager software
version 2.0. Analyses were performed in triplicate and the results
expressed in pg of cytokines/mL of supernatant.
Analysis of Cytotoxic Activity by Cytofluorometry
3610
6 LB1319-MEL or Jurkat target cells were stained green
(FL-1) with PKH67 (Sigma-Aldrich) and then washed twice to
completely remove the fluorescent reagent. Stained target cells
were then diluted at 5610
3 cells per 50 mL of culture medium.
The effector cells (E) were incubated with the stained target cells
(T) for 4 h at 37uC at different E/T ratios: 0,2:1; 0,6:1; 6:1; 20:1
and 60:1 in 96–well plates (Dutsher) in triplicate. The supernatant
of each well was then discarded and 150 mL of culture medium
containing propidium iodine (PI, FL-3) at 50 mg/mL was added.
Cytotoxicity was analyzed immediately on a FACS Calibur (BD
Pharmingen). The percentage of cytotoxicity was calculated as the
total number of dead target cells, stained both green (FL-1+) and
red (FL-3+), divided by the total number of target cells (all green
cells). The following equation was used:
% cytotoxicity~100|
%F L {1zandFL{3z ðÞ
%F L {1zandFL{3z ðÞ z%F L {1zandFL{3{ ðÞ
Results
Vaccination of Syngeneic Mice with mIFN-c and GGTI-298
Pretreated B16F10 Cells Induces Resistance to Untreated
Tumor Growth
To test whether pharmacological treatment of melanoma cells
with IFN-c and GGTI-298 could produce suitable cells for
vaccination a murine model was used: B16F10 cell line, a poorly
immunogenic and MHC-I negative melanoma of spontaneous
origin, was injected in the syngeneic C57Bl/6 mice. These
melanoma cells were chosen because we have previously shown
that pretreatment of B16F10 cells with mIFN-c associated with
GGTI-298 stimulates their immunogenicity through MHC-I and
costimulatory molecules expression and thereby their ability to
generate specific CD8 T lymphocytes [1]. To evaluate whether
this pharmacologically pretreated B16F10 cells were able to elicit
resistance to challenge with untreated tumor cells, mice were
vaccinated once s. c. with 2610
5 irradiated (100 Gy) and
pretreated cells and challenged s.c. with 1610
5 B16F10 cells one
month later. The efficiency of vaccination by B16F10 cells
pretreated with medium alone (NT), mIFN-c (50 UI/mL) (IFN),
GGTI-298 (10 mM) (GGTI) or mIFN-c (50 UI/mL) associated
with GGTI-298 (10 mM) (IFN+GGTI) were compared. The mice
of these 4 groups were monitored every 3 days after tumor
challenge, and the tumor surfaces were measured. The results
showed that vaccination with pretreated B16F10 cells, induce
protection against tumor growth in all groups but that the
vaccination with mIFN-c plus GGTI-298 was much more efficient
as 60% of mice in this group remained tumor free two months
after challenge (Figure 1B). Furthermore, tumors grow significant-
ly slower in this group as compared to tumors in the other groups
(Figure 1A). These results show that in vitro pretreatment of
B16F10 melanoma cells with mIFN-c and GGTI-298 render them
immunogenic cells usable for vaccination protocols.
Vaccination with mIFN-c and GGTI-298 Pretreated
B16F10 Cells Induces Resistance to Pulmonary
Metastases Implantation
We next tested the ability of these pharmacologically pretreated
B16F10 cells to induce, through vaccination, a protection against
pulmonary metastases implantation. Again syngeneic mice were
vaccinated as previously described and challenged intra-venously
Figure 1. Vaccination of syngeneic mice with mIFN-c+GGTI-298
pretreated B16F10 cells induces resistance to untreated tumor
growth. C57BL/6 mice were vaccinated with untreated B16F10 cells ;
mIFN-c (50 IU/mL); GGTI-298 (10 mM); or mIFN-c (50 IU/mL) and GGTI-
298 (10 mM) pretreated B16F10 cells. (A) One month after vaccination
tumor growth was measured after s.c. injection of 1610
5 live B16F10
cells, by Vernier caliper every 3 days. Groups of 6 or 7 C57Bl/6 mice were
tested. Data are representative of three independent experiments. (B)
The number of tumor free mice were calculated for each kind of
vaccination. Results are pooled for the three independent experiments.
doi:10.1371/journal.pone.0009043.g001
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4 B16F10 cells one month later. Four groups of mice
were vaccinated with B16F10 cells either untreated, or pretreated
with mIFN-c (50 UI/mL), GGTI-298 (10 mM), or mIFN-c
(50 UI/mL) plus GGTI-298 (10 mM). All mice were sacrificed
15 days after tumor challenge and pulmonary macro- and micro-
metastases were quantified as illustrated in Figure 2A and B. The
results showed that vaccination with mIFN-c plus GGTI-298
pretreated B16F10 cells is by far more efficient to protect against
pulmonary metastases implantation (Figure 2B).
Altogether, these results show that pretreatment of B16F10
melanoma cells with a combination of mIFN-c and GGTI-298
induces modifications of these cells such that they become
immunogenic cells able to induce by vaccination protection
against tumor growth and pulmonary metastases implantation.
GGTI-298 Enhances hIFN-c-Induced Expression of MHC-I
but Not MHC-II in Human Melanoma Cells
MHC molecules present peptides derived from TAA on tumor
cell membranes. MHC-I presents peptides from cytoplasmic
proteins that are recognized by cytotoxic T CD8+ lymphocytes,
with responses leading to clinical tumor regression [3] [5] [6].
Thus, strong expression of MHC-I on tumor cell membranes
favors tumor immune rejection. We tested the ability of in vitro
treatment of human melanoma cells with hIFN-c and GGTI-298
to enhance membrane MHC-I expression, and in particular the
MHC-I allele able to present an immunodominant TAA peptide.
For this purpose, we cultivated LB1319-MEL cells, which are
spontaneously HLA-ABC positive and express HLA-A0201
molecules, for 4 days with GGTI-298 (10 mM), either alone or
with hIFN-c (50 IU/mL). A concentration of 10 mM of GGTI-298
prevented protein isoprenylation and was only weakly toxic in our
culture conditions (data not shown). Higher concentrations were
not used due to their cellular toxicity. As shown in Figure 3,
despite a strong constitutive expression of MHC-I and HLA-
A0201, GGTI-298 treatment enhanced significantly the hIFN-c-
induced membrane expression of these molecules in LB1319-MEL
cells (p,0,001). In this cell line expression of HLA-ABC and
HLA-A0201 increased in a dose-dependent manner in hIFN-c-
treated cells, reaching a steady-state level at 50 IU/mL, but these
expressions were further significantly enhanced by addition of
GGTI-298 (10 mM). However, GGTI-298 alone (10 mM) did not
significantly modify expression of MHC-I and in particular HLA-
A0201 (Figures 3A and 3B).
MHC-II molecules present peptides derived primarily from
extra-cellular proteins, and these are recognized by auxiliary CD4+
T lymphocytes. Some of these CD4+ T cells ‘‘help’’ CD8+ T
lymphocytes via cytokine production. With few exceptions, tumor
cells do not express MHC-II molecules. We tested the ability of in
vitro treatment with hIFN-c alone or with GGTI-298, to induce
membrane MHC-II (HLA-DP,-DQ,-DR) expression in MHC-II-
negative LB1319-MEL cells. As shown in Figure 3A and 3B,
treatment with hIFN-c (50 IU/mL) for 4 days did not induce HLA-
DP,-DQ,-DR expression; nor did higher concentrations up to 100
IU/mL or 500 IU/mL (data not shown). Moreover addition of
GGTI-298 (10 mM) did not modify MHC-II expression.
Overall, these results show that GGTase I inhibition further
enhanced hIFN-c–induced MHC-I membrane expression in these
MHC-I positive human melanoma cell lines. In contrast, these
cells remained MHC-II-negative after such treatments.
GGTI-298 Enhances hIFN-c-Induced TAP1 and TAP2 in
LB1319-MEL Cells
Peptide presentation by MHC-I antigens is linked to the
coordinated activity of multiple components of the MHC-I antigen
processing pathway (APP), including the peptide transporters TAP1
and TAP2 [2], the chaperon protein tapasin, and the subunits of the
multicatalytic proteasome (PA28, LMP2, LMP7, and LMP10).
Seligeretal.[20] demonstrated thatthedefectinMHC-Iexpression
inthe B16F10murine tumormodelwas linkedto downregulation of
proteins in the MHC-I APP, which could be corrected by mIFN-c
administration. We previously demonstrated in the same murine
model that treatment with GGTI-298 enhances mIFN-c-induced
TAP1 expression [1]. In the current study we used the LB1319-
MEL human melanoma model to investigate the effects of 4 days of
in vitro treatment with hIFN-c (50 IU/mL) and/or GGTI-298
Figure 2. Syngeneic mice vaccination with mIFN-c+GGTI-298
pretreated B16F10 cells induces resistance to pulmonary
metastases implantation. Four groups of C57Bl/6 mice were
vaccinated with untreated B16F10 cells (NT); mIFN-c (50 IU/mL) (IFN);
GGTI-298 (10 mM) (GGTI); or mIFN-c (50 IU/mL) and GGTI-298 (10 mM)
(IFN+GGTI). One month later, they were challenged intravenously with
untreated B16F10 cells. (A) Metastases were screened macroscopically
and microscopically as illustrated. (B) Lungs from the 4 groups of mice
were slidded vertically and micro-metastases were counted and
reported to the lung surfaces (mm
2).
doi:10.1371/journal.pone.0009043.g002
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LMP7, and LMP10 proteins (Figure 4).
As observed in the murine model, treatment with hIFN-c alone
up-regulated the expression of all measured proteins of the MHC-I
APP, while treatment with GGTI-298 alone had no significant effect
(Figure 4A). When LB1319-MEL cells were jointly treated with
GGTI-298 and hIFN-c, TAP1 and TAP2 expression underwent a 3-
fold and 1,5 fold increase, respectively, relative to expression
following treatment with hIFN-c alone (Figure 4A). Addition of
GGTI-298 had no significant effect on the hIFN-c-induced
expressionofthe othertestedproteinsoftheMHC-IAPP(Figure4A).
The results obtained by western blotting of TAP1 and TAP2
were confirmed by flow cytometry in LB1319-MEL cells treated
with hIFN-c and GGTI-298, permeabilized, and stained with
anti-TAP1 or anti-TAP-2 antibodies (Figure 4B). As shown in
Fig.4C, TAP1 expression increased dose-dependently in hIFN-c-
treated cells, reaching a steady-state level at 50 IU/mL; addition
of GGTI-298 (10 mM) further increased expression. This increase
is statistically significant with a p,0,05.
Collectively, these results show that GGTase I inhibition
enhances hIFN-c-induced TAP1 and TAP2 expression in this
human melanoma cell line.
Figure 3. GGTI-298 enhances hIFN-c-induced MHC-I expression on human melanoma cells. LB1319-MEL cells were grown for 4 days in
culture medium (filled profiles) or in the presence of hIFN-c alone (50 IU/ml) (thin lines) or GGTI-298 alone (10 mM) (dotted lines) or IFN-c and GGTI-
298 (thick lines). A) HLA-A,B,C ; HLA-A0201; HLA-DP,DQ,DR and isotypic controls expressions were measured by flow cytometry after staining with PE-
conjugated mAbs. B) HLA-A0201 (White Column) HLA-A,B,C (Grey Column) and HLA-DP,DQ,DR (Black Column) membrane expressions were tested by
cytofluorometry on LB1319-MEL cells after 4 days treatment with either increasing doses of hIFN-c (0, 25, 50 and 100 IU/ml) or with the combination
of hIFN-c (50 IU/ml) and GGTI-298 (10 mM). Results are expressed in ISF, related to isotype controls, as indicated in Material and Methods. Data are
representative of 3 independent experiments.
doi:10.1371/journal.pone.0009043.g003
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Expression of a Stimulatory Molecule CD86 and Down
Regulates the IFN-c-Induced Expression of an Inhibitory
Molecule PD-1L
There are two families of costimulatory molecules expressed in
antigen presenting cells (APCs) and some tumor cells: B7 and
TNF/TNF receptor (TNF-R). Previously [1] we reported that in
vitro treatment with GGTI-298 induces a dose-dependent increase
in the membrane expression of CD80 and CD86 costimulatory
molecules in the murine melanoma cells B16F10 and an increase
in CD86 in two human melanoma cell lines, including LB1319-
MEL. Here we confirmed that LB1319-MEL cells spontaneously
express the costimulatory molecule CD86, and that this expression
is unaffected by hIFN-c treatment alone but strongly enhanced
following treatment with GGTI-298 alone or in combination with
hIFN-c (Figure 5A). CD86 expression increased dose-dependently
in GGTI-298-treated cells, reaching a steady-state level at 10 mM.
Addition of hIFN-c (50 IU/mL) did not induce further increased
expression (Figure 5C).
Furthermore, FACS analysis showed that LB1319-MEL cells
spontaneously express in their membrane the inhibitory molecule
PD-1L [21]. Its expression was up regulated by hIFN-c treatment
and significantly (p,0,05) down regulated by GGTI-298 addition
(Figure 5D).
Altogether, these results show that GGTI-298 treatment
modifies the level of expression of costimulatory molecules which
are spontaneously expressed on the membrane of LB1319-MEL
melanoma cells. Interestingly, it appears that this pharmacological
treatment increases the immunogenicity of the tumor cells because
it enhances the expression of the stimulatory CD86 molecules and
it down regulates the IFN-c-induced expression of the inhibitory
molecule PD-1L.
In Vitro Stimulation of PBMC from Healthy Donors Using
LB1319-MEL Cells Pretreated with hIFN-c and GGTI-298
Induces CD8 T Lymphocyte Activation
We next wished to test the ability of this combined treatment to
convert LB1319-MEL melanoma cells into stimulator cells able to
induce an enhanced in vitro activation of lymphocytes and
particularly of CD8 T lymphocytes. For this, we twice stimulated
PBMC from 3 healthy HLA-A0201 donors (HD) in vitro with
LB1319-MEL melanoma cells which had been pretreated with
hIFN-c and/or GGTI-298, washed twice and then irradiated as
described in Materials and Methods. Activation of different
lymphocytes subpopulations was analyzed by flow cytometry.
Stimulation with hIFN-c and especially hIFN-c associated with
GGTI-298 pretreated tumor cells enhanced the activation of CD8+
lymphocytes. These activated cells expressed the activation marker
CD69, which is expressed rapidly upon activation [22]. In these
conditions CD4+ and NK cells activation remains unchanged (data
notshown).Butwedetected a 2-foldincreaseinCD8+/CD69+ cells
following stimulation of the PBMC with LB1319-MEL cells
pretreated with hIFN-c and GGTI-298 versus hIFN-c alone
(Figure 6). This shows that pretreatment of LB1319-MEL cells
with hIFN-c and GGTI-298 increases their efficiency to activate
CD8 T lymphocytes from PBMC of HLA-A0201 HD in vitro.
In Vitro Stimulation of PBMC from HD Using hIFN-c and
GGTI-298-Treated LB1319-MEL Melanoma Cells Induces
IFN-c Release
In an effort to determine whether LB1319-MEL cells pretreated
with hIFN-c and GGTI-298 can become stimulatory cells capable
of inducing the functional activation of co-cultivated lymphocytes,
we analyzed the cytokine production in the co-cultures. By
multiplex analysis for IL-2, IL-4, IL-10, and IFN-c (Linco
Multiplex), we investigated the TH1/TH2 profile of cytokines
released by the stimulated cells. IL-2 and IFN-c secretion is
representative of the TH1 profile, mainly implicated in cellular
immune responses, whereas IL-4 and IL-10 secretion is associated
Figure 4. On LB1319-MEL cells, GGTI-298 enhances hIFN-c-
induced TAP1 and TAP2 expressions. LB1319-MEL cells were
cultivated for 4 days in the presence or in the absence of hIFN-c (50 IU/
ml) and/or GGTI-298 (10 mM) as indicated. A) The expression of molecules
implicated in the MHC-I Ag processing pathway were tested in these
treated tumor cells. b- a c t i nw a su s e da sp r o t e i nl o a d e dc o n t r o l .T h e
expressions were quantified by calculating the ratio between the protein of
interest and the b-actin. We defined the ratio of relevant protein over b-
actin for untreated cells equal to 1. B) Expressions of TAP1 and TAP2
proteins in these in vitro treated and permeabilized LB1319-MEL were
tested by flow cytometry using TAP1 and TAP2 specific mAbs and a PE-
conjugated secondary Ab. C) TAP1 membrane expression was also tested
by cytofluorometry on LB1319-MEL cells after 4 days treatment with either
increasing doses of hIFN-c (0, 25, 50 and 100 IU/ml) or with the
combination of hIFN-c (50 IU/ml) and GGTI-298 (10 mM). Results are
expressed in ISF, related to isotype controls, as indicated in Material and
Methods. Data illustrated are representative of 3 independent experiments.
doi:10.1371/journal.pone.0009043.g004
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response and/or negative regulation of the immune response [23].
Secretion levels were examined in the supernatants of co-cultures
24 h after the second stimulation of the PBMC with the pretreated
tumor cells.
A significant increase in hIFN-c secretion was observed when
the LB1319-MEL melanoma stimulatory cells were pretreated
with hIFN-c alone, which was further enhanced following
pretreatment with a combination of hIFN-c and GGTI-298
(Table 1). These stimulations also induced an increased secretion
of hIL-2, the concentration of which only reached moderate levels
in the supernatants, perhaps due to autocrine consumption by
proliferating T lymphocytes (Table 1). These results suggest a TH1
cytokine secretion in our culture conditions.
However, pretreatment of the LB1319-MEL stimulatory cells
with hIFN-c alone also induced an increase in hIL-4 secretion by
Figure 6. Enhanced activation of CD8+ T lymphocytes in PBMC
co-cultivated with LB1319-MEL cells pre-treated with hIFN-
c+GGTI-298. PBMC from HD HLA-A0201 were stimulated twice with
LB1319-MEL cells either untreated; or pretreated with hIFN-c (50 IU/mL);
GGTI-298 (10 mM); or hIFN-c (50 IU/mL) plus GGTI-298 (10 mM). CD8+
activation was evaluated by CD69 membrane expression. Experiments
were performed in triplicate with PBMC from one healthy donor
representative of one other giving comparable results.
doi:10.1371/journal.pone.0009043.g006
Table 1. Enhanced IFN-c secretionbyPBMC co-cultivatedwith
LB1319-MEL cells pre-treated in vitro with hIFN-c+GGTI-298.
Cytokines concentration (+/- SD)
IL-2 IFN-c IL-4 IL-10
NT 1,5 (+2/1) 71,1 (+/25) 5,98 (+/23) 37,6 (+/26)
IFN 3,9 (+/22) 206 (+/224) 42,7 (+/23) 38,8 (+/22)
GGTI 1,7 (+/21) 148 (+/219) 18,3 (+/26) 39,3 (+/27)
IFN+GGTI 4,2 (+/21) 418 (+/24) 36,3 (+/21) 37,7 (+/27)
PBMC from 3 HLA-A0201 HD were stimulated twice in vitro with LB1319-MEL
cells untreated (NT); or pretreated with 50 UI/mL hIFN-c (IFN); 10 mM GGTI-298
(GGTI); or the combination of 50 UI/mL hIFN-c and 10 mM GGTI-298 (IFN+GGTI)
as indicated. 24h after the second in vitro stimulation, cytokine secretions in the
culture supernatants were measured by Multi-Plex human cytokine assays.
Results are illustrated in pg/mL for secretions of IFN-c, IL-2, IL-4 and IL-10. Data
are shown as mean (+/2 standard deviation) of duplicate values and were
obtained from one donor representative of the two others giving comparable
results.
doi:10.1371/journal.pone.0009043.t001
Figure 5. On LB1319-MEL cells, GGTI-298 induces enhance-
ment of CD86 and reduction of IFN-c-induced PD-1L expres-
sion. Membrane expression of CD86 (A) and its isotype control (B) was
determined by flow cytometry with PE-conjugated specific antibodies
on LB1319-MEL cells after 4 days in vitro treatment with medium alone
(filled profiles); hIFN-c (50 IU/mL) alone (thin lines); GGTI-298 (10 mM)
alone (dotted lines); or the combination of both (thick lines). Data are
representative of three independent experiments. C) CD86 membrane
expression was also tested by cytofluorometry on LB1319-MEL cells
after 4 days treatment with either increasing doses of GGTI-298 (0, 5,10,
15 and 20 mM) or with the combination of hIFN-c (50 IU/ml) and GGTI-
298 (10 mM). Results are expressed in percentage of CD86 positive cells.
D) Membrane expression of inhibitory molecule PD-1L was determined
by flow cytometry with PE-conjugated specific Ab on LB1319-MEL cells
after 4 days in vitro treatment with or without hIFN-c (50 IU/ml) and/or
GGTI-298 (10 mM). Results are expressed in ISF, related to isotype
controls, as indicated in Material and Methods. Data are representative
of 3 independent experiments.
doi:10.1371/journal.pone.0009043.g005
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showed no enhancement (Table 1). Moreover, no significant
changes in IL-10 levels were observed in the different co-culture
conditions (Table 1).
Altogether, these results do not reveal a strict TH1 or TH2
profile of cytokine secretion, but they do show that the
pretreatment of LB1319-MEL cells with hIFN-c and GGTI-298
induces modifications of these cells such that they induce increased
hIFN-c secretion by the cells present in the co-culture.
LB1319-MEL Cells Pre-Treated In Vitro with hIFN-c and
GGTI-298 Enhance Specific Anti-Melanoma Cytotoxic
Activity of Co-Cultivated PBMC
IFN-c can be secreted by NK cells or CD8 T effector
lymphocytes and is linked to efficient cytotoxic activity. We next
wished to determine whether pretreated LB1319-MEL cells
become stimulatory cells capable of inducing anti-melanoma
cytotoxic effector cells from the co-cultivated PBMC of HLA-
A0201 compatible HD. The cytotoxic activity of these stimulated
PBMC was then tested. As cytotoxic cells express the lysosomal
membrane protein (CD107a) [24], the expression of this molecule
was analyzed among the CD8 positive cells present in these
stimulated PBMC. As shown in Figure 7A, CD107a positive cells
are significantly increased in the co-culture stimulated by LB1319-
MEL cells pretreated by IFN-c and GGTI-298. Moreover the
cytotoxic activity of these stimulated PBMC was also tested
directly by their killing capacity on both an unspecific target cell
line Jurkat and on the specific one LB1319-MEL. The effector
cells obtained after the co-culture had similar non-specific
cytotoxic capacity whatever the pretreatment of the stimulator
Figure 7. Enhanced specific cytotoxic activity in PBMC co-cultivated with LB1319-MEL cells pre-treated with hIFN-c+GGTI-298.
Cytotoxic activities of in vitro stimulated PBMC were tested after two stimulations with LB1319-MEL cells either untreated or pretreated with hIFN-c
(50 IU/mL); GGTI-298 (10 mM); or hIFN-c (50 IU/mL) plus GGTI-298 (10 mM). A) Cytotoxicity was evaluated by CD107a expression on CD8+ gated T
lymphocytes. Cytotoxic activity was also tested on an unspecific target cell: B) Jurkat and the specific one: C) LB1319-MEL. Experiments were
performed in triplicate with PBMC from one healthy donor representative of one other giving comparable results.
doi:10.1371/journal.pone.0009043.g007
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different pretreatments induced different levels of specific cytotoxic
activity detected on untreated LB1319-MEL target cells
(Figure 7C). Indeed we found a significantly increased cytotoxicity
following the stimulation of PBMC by the combined hIFN-c plus
GGTI-298 pretreated melanoma cells. The pretreatment with
hIFN-c or GGTI-298 alone induced intermediate lytic activity
and untreated melanoma cells induced very low specific
cytotoxicity (Figure 7C).
These results show that pretreatment of LB1319-MEL mela-
noma cells with a combination of hIFN-c and GGTI-298 induces
modifications of these cells such that they become stimulator cells
able to enhance specific anti-melanoma cytotoxic effectors in co-
cultivated HLA-compatible PBMC from HD.
In Vitro Stimulation of PBMC from HD Using hIFN-c and
GGTI-298-Pretreated LB1319-MEL Cells Increases the
Proliferation of Tumor-Specific CD8 T Lymphocytes
Labeled with MART-1/HLA-A2 Tetramers
The specific cytotoxicity observed after co-cultivating PBMC
with LB1319-MEL cells pretreated with the combination of hIFN-
c and GGTI-298, suggests that these melanoma cells develop the
ability to induce a specific anti-tumor immune response in vitro,
likely linked to the increased proliferation of specific CD8 T
lymphocytes. To test this hypothesis, PBMC from 3 HLA-A0201
HD were twice stimulated in vitro with LB1319-MEL cells
pretreated with hIFN-c and/or GGTI-298 as before. The T
lymphocyte subpopulations present in the co-culture were then
analyzed by flow cytometry. The LB1319-MEL melanoma cell
line expresses peptides on the membrane, obtained from MelanA/
MART-1 proteins and associated with HLA-A0201 molecules, in
particular the immunodominant peptide EAAGIGILTV [19].
LB1319-MEL specific CD8 T lymphocytes should therefore
express TCR specific for this HLA-A0201-presented peptide,
which can be labeled with MART-1/HLA-A0201 tetramers. We
observed a significant increase of the CD8 subpopulation labeled
with these tetramers in the 3 tested donors (Table 2 and illustrated
for one HD in Figure 8A). On the contrary, these stimulated
PBMC have similar levels of non-specific TCR, detected with
EBV/HLA0201 tetramers, whatever the pretreatment of the
stimulator LB1319-MEL cells as illustrated in Figure 8B. How-
ever, the control PBMC cultures stimulated by an HLA-A0201
EBV immortalized lymphoblastoid cell line (L1-EBV) were
strongly positive with these EBV/HLA0201 tetramers (Figure 8B).
These results show that in vitro stimulation of PBMC from HLA-
A0201 HD, with hIFN-c and GGTI-298 pretreated LB1319-MEL
cells, induces the enhancement of the specific anti-tumor CD8 T
lymphocyte subpopulation.
Discussion
Melanoma is a highly lethal cutaneous tumor, killing affected
patients through multiple, poorly immunogenic metastases.
Several previous studies have investigated vaccine-based and
curative approaches for inducing an immune response against
melanoma cells. Different protocols have been investigated for
obtaining cellular tools necessary for vaccination or curative
adoptive transfer, with the intent of stimulating PBMC or tumor
infiltrating lymphocytes (TIL) from the patients in vitro before re-
effusion [3] [19]. The use of pulsed DC [6] or tumor-DC hybrids
[7] is very attractive however the development of highly
immunogenic melanoma cell lines also represents another
interesting approach. We recently reported that a combination
of GGTI-298 and mIFN-c increased the immunogenicity of a
murine melanoma cell line[1]. Using the melanoma cell line
B16F10, we showed that treatment with GGTI-298 and mIFN-c
inhibited tumor growth in vivo by a mechanism involving the
activation of specific CD8 T lymphocytes.
Furthermore, in the present study, we showed that vaccination
with IFN-c and GGTI-298 pretreated B16F10 melanoma cells
reduces tumor recurrence and also exert an anti-metastatic effect.
Indeed, in vivo vaccination of syngeneic mice with pharmacolog-
ically pretreated melanoma cells induces tumor growth slowing
down and reduction of pulmonary metastases implantation.
Moreover, we have demonstrated here that the same treatment
applied to a cutaneous metastatic human melanoma cell lines,
modifies the expression of molecules in the cellular membrane in a
manner favoring a specific anti-tumor immune response. Our
results indicate that GGTI-298 treatment inhibits the activity of a
geranylgeranylated protein involved in hIFN-c induced HLA-
A0201 expression. As previously observed in the murine
melanoma model, the GGTase I inhibition enhances IFN-c-
induced MHC class I expression through a mechanism involving
TAP1 and TAP2 over-expression.
The human melanoma cell line used is obtained from a
cutaneous metastasis and it express spontaneously the costimula-
tory molecule CD86 on its membrane, which is in agreement with
findings of Hersey et al. showing that few melanoma metastases
cells express CD80 or CD86 [25]. So, our results show that GGTI-
Table 2. PBMC stimulation with hIFN-c+GGTI-298 pretreated LB1319-MEL cells induces CD8+ and MART-1/HLA-A0201+ specific
cells proliferation.
Percentage (%) of cells CD8+ and MART1/HLA-A2+ Fold Induction (FI) of cells CD8+ and MART1/HLA-A2+
HD1 HD2 HD3 HD1 HD2 HD3
NT 1,5 0,29 0,07 1 1 1
IFN 2,7 0,39 0,11 1,8 1,34 1,57
GGTI 1,03 0,65 0,03 0,68 2,24 0,42
IFN+GGTI 4,8 1,13 0,35 3,2 3,9 5
PBMC from 3 HLA-A0201 HD were stimulated twice in vitro with LB1319-MEL cells untreated (NT); or pretreated with 50 UI/mL hIFN-c (IFN); 10 mM GGTI-298 (GGTI); or
with a combination of 50 UI/mL hIFN-c and 10 mM GGTI-298 (IFN+GGTI) as indicated. At the end of the culture period, PBMC were stained with FITC-conjugated anti-
CD8 monoclonal antibody and with PE-conjugated MART-1/HLA-A2 tetramers. Percentages of double positive CD8+ and MART-1/HLA-A2 tetramers+ PBMC are shown.
Fold induction between double positive CD8+ and MART-1/HLA-A2+ cells obtained after co-culture with untreated or pre-treated LB1319-MEL cells is shown. We
defined the percentage of double positive cells obtained with the untreated melanoma cells (NT) as equal to 1 and compared this to the values obtained in the other
culture conditions.
doi:10.1371/journal.pone.0009043.t002
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melanoma cell membranes. This suggests that GGTI-298 may
increase the membrane localization rather than expression levels
of CD86, as we recently demonstrated with FasL protein on the
murine melanoma cell line B16F10 [26].
Due to its expression of an HLA-I haplotype (HLA-A0201) and
a TAA (MelanA/MART-1), both expressed on a large proportion
of human melanoma cells [27], the LB1319-MEL melanoma cell
line is an interesting and representative cell line. DC are the most
potent and efficient APC in the immune system. They express high
levels of MHC-I- and MHC-II-encoded gene products and
costimulatory molecules on their membrane. By triggering the
over-expression of MHC-I molecules and costimulatory molecules,
in vitro treatment with a combination of hIFN-c and GGTI-298
modifies LB1319-MEL melanoma cells such that they acquire
some characteristics of stimulatory APC and become more
efficient stimulator cells able to activate CD8 T lymphocytes from
PBMC of HLA-compatible HD.
Our results show that the modifications induced by the
pretreatment of LB1319-MEL melanoma cells with hIFN-c and
GGTI-298 promote an anti-tumor immune response by increasing
the number of specific CD8 T lymphocytes labeled with MART-
1/HLA-A2 tetramers. Furthermore, in vitro stimulated PBMC are
able to secrete significant amounts of hIFN-c and develop specific
anti-melanoma cytotoxic activity. These abilities render them
suitable for anti-tumor immune surveillance [18] [27].
In conclusion, according to the results obtained with the murine
and the human melanoma models, a combined ex-vivo pharma-
cological treatment with hIFN-c and GGTI-298, may represent a
promising approach to produce specific anti-melanoma effector
cells and immunogenic melanoma cells suitable for vaccination.
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